The coming week could prove to be one of the most significant for investors in the US markets. From January 19th to 23rd, over fifty companies will release their fourth-quarter 2025 results, including some of Wall Street's most followed names. Netflix, Intel, Johnson & Johnson, Procter & Gamble: these aren't just large-cap companies, but companies whose numbers can influence the entire market's sentiment and provide valuable insights into the direction of the US economy.

What makes this earnings season particularly interesting isn't just the numbers themselves, but the context in which they're released. After a 2025 marked by falling interest rates, geopolitical tensions, and the explosion of artificial intelligence, investors are seeking confirmation: are companies actually benefiting from this new environment? Are margins holding up? Is growth sustainable? The answers will come in the coming days.

Tuesday, January 20: Netflix and the Ad Growth Test

Tuesday promises to be a busy day, with several big-cap stocks ready to reveal their results. But everyone's attention will inevitably be drawn to Netflix , which will release its results after the markets close.

The streaming giant enters this event in a unique position. On the one hand, the stock has lost approximately 34% from its June 2025 highs, significantly underperforming the S&P 500. On the other, its fundamentals continue to show solidity. Analysts expect earnings growth of 28% compared to the same period last year, driven by disciplined cost management and the expansion of its ad-supported tier.

What the market will want to understand is whether Netflix can truly transform advertising into a primary growth driver. The signs are encouraging: the company aims to double advertising revenue by 2025 and is working on interactive features that could open up new opportunities. With over 300 million subscribers in 190 countries, the potential is there. But there's also a shadow: the $82.7 billion acquisition of Warner Bros. Discovery, which has raised eyebrows among several analysts due to its high price tag and execution risks. Guidance for 2026 will be crucial to understanding whether management views this deal as transformative or simply defensive.

The banking sector opens the dance

Even before Netflix, several major financial institutions will be on the scene on Tuesday morning. Fifth Third Bancorp (FITB) will report earnings before the market closes, with EPS expected to be $1.02, up 13% year-over-year. The Cincinnati-based regional bank is experiencing interesting momentum thanks to its recent acquisition of Comerica, which should significantly strengthen its geographic presence and operational scale.

At a valuation of approximately 12 times 2026 earnings and a 3.3% dividend yield, Fifth Third represents an attractive option for those seeking exposure to the banking sector with a reasonable risk-return profile. Analysts maintain an overall "Moderate Buy" rating, with an average price target implying an upside of 13%.

In the afternoon, after the close, it will be the turn of Interactive Brokers (IBKR) , the digital broker that has built its success on competitive commissions and a technologically advanced platform. The consensus forecasts EPS of $0.50-$0.52, essentially stable compared to the previous year. The real focus will be the trend in DART (Daily Average Revenue Trades), which grew 29% year-over-year in Q3. If trading activity were to slow, there could be room for a correction in the currently rather high valuations.

Wednesday 21st: Healthcare takes center stage with Johnson & Johnson

Wednesday will be dominated by the healthcare sector, with Johnson & Johnson releasing results before the markets open.

The New Jersey-based pharmaceutical giant is coming into this event in great shape: its stock has gained over 43% in the past year, significantly outperforming both the S&P 500 and the healthcare sector. The drivers of this performance are clear: a solid pharmaceutical pipeline, with drugs such as Carvykti (expected to grow 87%) and Tremfya (+40%) gaining market share, and a continuing expansion of the MedTech segment.

Analysts maintain a "Moderate Buy" rating with an average price target of $211, but some see room up to $240. The recent acquisition of Halda Therapeutics for $3.05 billion confirms management's appetite for external growth opportunities, even though it will have a dilutive impact of approximately $0.20 on earnings between 2025 and 2026.

Also on Wednesday, before the market opens, Halliburton (HAL) will provide an important gauge for the oil services sector. EPS is expected to be $0.54, down 23% from the previous year, reflecting the energy sector's challenges in 2025. However, cost-cutting initiatives appear to be bearing fruit, with operating margins improving. Monitor for any comments regarding opportunities in Venezuela, following Trump's oil blockade announcement, which sent the stock soaring 8% in early January.

Thursday 22nd: The grand finale of tech and consumer goods

The busiest day of events will be Thursday, with a combination of sectors rarely seen in a single day.

In the morning, before the market opens, it will be the turn of Procter & Gamble (PG) , the consumer goods giant that brings brands like Tide, Pampers, and Gillette to American homes. Expectations are for EPS of $1.87, marginally lower than the prior year, on revenues of $22.36 billion. Management has already warned that this will be the weakest quarter of the fiscal year, with pressure from tariffs (estimated impact of $1 billion pre-tax) and commodity costs.

Also on Thursday morning, GE Aerospace (GE) will provide crucial guidance on the aviation sector, while Abbott Laboratories (ABT) and Freeport-McMoRan (FCX) will round out the picture with healthcare and commodities.

But it is in the afternoon, after closing, that perhaps the most awaited surprises will arrive.

Intel is the most closely watched turnaround story in tech. After years of relative decline compared to AMD and NVIDIA, the Santa Clara giant is trying to reposition itself as a relevant player in the era of artificial intelligence. Quarterly numbers will likely be weak, with EPS down from the previous year, but the market will be looking beyond: progress in advanced chip production, traction in the AI segment, and especially the roadmap for 2026. The stock has already rallied strongly (+88% in one year), so there is plenty of room for disappointment.

Along with Intel, Intuitive Surgical (ISRG) , the world leader in robotic surgery, will also be on the scene on Thursday evening. The company has already released very positive preliminary figures: Q4 revenues of approximately $2.87 billion (+19% YoY), da Vinci system procedures up 17%, and an acceleration in the positioning of the new da Vinci 5 system. Analysts are expecting EPS of $2.25, but the real news is the 2026 guidance: the company expects procedure growth of 13-15%, a figure that has disappointed some investors accustomed to higher rates. Hence the stock's recent weakness despite the strong numbers.

Other titles not to be underestimated

Beyond the big names, there are some interesting stories to watch. 3M Company (MMM) , which has gained nearly 50% over the past year, will report earnings on Tuesday morning with expectations for EPS of $1.82 (+8.3%). Following the spinoff of its healthcare division, the company is demonstrating renewed operational discipline that investors are rewarding.

United Airlines (UAL) , due Tuesday evening, represents an interesting gauge of the travel industry. Despite expectations for EPS to decline 8.9% to $2.97, management expects this to be the best quarter ever in terms of revenue. The stock enjoys strong analyst support, with 20 "Strong Buy" ratings out of 24 coverages.

Conclusions: Where to look in the coming months

This earnings week comes at a time of transition for the markets. Interest rates are falling (the Fed is at 3.5-3.75%), but it's unclear whether this will be enough to sustain economic growth. Stock valuations are high, especially in tech, and the market needs confirmation that earnings can justify current multiples.

For investors with a medium- to long-term horizon, this earnings season offers several interesting insights. In tech, Intel represents a turnaround bet with high risks and potential returns, while Intuitive Surgical offers exposure to robotic surgery with a more defensive profile. In the consumer sector, Procter & Gamble is going through a difficult period but maintains quality and attractive dividends. In the financial sector, Fifth Third Bancorp combines reasonable valuations and growth thanks to the acquisition of Comerica. And in healthcare, Johnson & Johnson remains a pillar for those seeking stability and moderate growth.

As always, numbers alone aren't enough: it will be crucial to listen to management's comments on future prospects. In a market that already prices in so much perfection, even small disappointments can translate into significant movements. But for those who wait, these volatilities often create the best buying opportunities.